- Home
- OPRT vs IKT Comparison
OPRT vs IKT Comparison
Compare OPRT & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPRT
- IKT
- Stock Information
- Founded
- OPRT 2005
- IKT 2008
- Country
- OPRT United States
- IKT United States
- Employees
- OPRT N/A
- IKT N/A
- Industry
- OPRT Finance: Consumer Services
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- OPRT Finance
- IKT Health Care
- Exchange
- OPRT Nasdaq
- IKT Nasdaq
- Market Cap
- OPRT 146.4M
- IKT 159.2M
- IPO Year
- OPRT 2019
- IKT 2020
- Fundamental
- Price
- OPRT $5.22
- IKT $2.27
- Analyst Decision
- OPRT Buy
- IKT Strong Buy
- Analyst Count
- OPRT 4
- IKT 2
- Target Price
- OPRT $5.17
- IKT $6.50
- AVG Volume (30 Days)
- OPRT 219.2K
- IKT 194.9K
- Earning Date
- OPRT 02-12-2025
- IKT 03-26-2025
- Dividend Yield
- OPRT N/A
- IKT N/A
- EPS Growth
- OPRT N/A
- IKT N/A
- EPS
- OPRT N/A
- IKT N/A
- Revenue
- OPRT $796,991,000.00
- IKT $1.00
- Revenue This Year
- OPRT N/A
- IKT N/A
- Revenue Next Year
- OPRT $2.36
- IKT N/A
- P/E Ratio
- OPRT N/A
- IKT N/A
- Revenue Growth
- OPRT N/A
- IKT N/A
- 52 Week Low
- OPRT $2.05
- IKT $1.12
- 52 Week High
- OPRT $5.23
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- OPRT 75.99
- IKT 38.70
- Support Level
- OPRT $3.67
- IKT $1.90
- Resistance Level
- OPRT $3.99
- IKT $2.37
- Average True Range (ATR)
- OPRT 0.22
- IKT 0.25
- MACD
- OPRT 0.09
- IKT -0.07
- Stochastic Oscillator
- OPRT 88.69
- IKT 34.91
About OPRT Oportun Financial Corporation
Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.